Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Moderna (MRNA) stocks

Learn how to easily invest in Moderna stocks.

Moderna is a biotechnology business based in the US. Moderna stocks (MRNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $142.85 – an increase of 3.94% over the previous week. Moderna employs 3,200 staff and has a trailing 12-month revenue of around $22.6 billion.

How to buy stocks in Moderna

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRNA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Moderna stock price (NASDAQ:MRNA)

Use our graph to track the performance of MRNA stocks over time.

Moderna shares at a glance

Information last updated 2022-06-27.
Latest market close$149.95
52-week range$115.61 - $497.49
50-day moving average $139.19
200-day moving average $219.63
Wall St. target price$219.33
PE ratio 4.2733
Dividend yield $0 (0%)
Earnings per share (TTM) $34.02

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99–$9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Moderna stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Moderna price performance over time

Historical closes compared with the close of $149.95 from 2022-07-01

1 week (2022-06-27) 3.16%
1 month (2022-06-01) 4.57%
3 months (2022-03-31) -12.95%
6 months (2021-12-31) -40.96%
1 year (2021-07-02) -36.00%
2 years (2020-07-02) 156.02%
3 years (2019-07-03) 879.43%
5 years (2017-06-30) N/A

Is Moderna under- or over-valued?

Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Moderna's P/E ratio

Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Moderna shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Moderna's EBITDA

Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.6 billion.

The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.

Moderna financials

Revenue TTM $22.6 billion
Operating margin TTM 71.93%
Gross profit TTM $13.9 billion
Return on assets TTM 50.42%
Return on equity TTM 139.99%
Profit margin 64.77%
Book value $42.69
Market capitalisation $57.8 billion

TTM: trailing 12 months

Moderna share dividends

We're not expecting Moderna to pay a dividend over the next 12 months.

Moderna share price volatility

Over the last 12 months, Moderna's shares have ranged in value from as little as $115.61 up to $497.49. A popular way to gauge a stock's volatility is its "beta".

MRNA.US volatility(beta: 1.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.6928. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moderna overview

Moderna, Inc. , a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co. , Inc. ; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site